Great Novel Therapeutics Biotech & Medicals
Taipei Exchange 7427.TWO
Great Novel Therapeutics Biotech & Medicals Capital Expenditure for the year ending December 31, 2023: USD -679.59 K
Great Novel Therapeutics Biotech & Medicals Capital Expenditure is USD -679.59 K for the year ending December 31, 2023, a -65.70% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
-
Great Novel Therapeutics Biotech & Medicals Capital Expenditure for the year ending December 31, 2022 was USD -410.14 K, a 59.40% change year over year.
-
Great Novel Therapeutics Biotech & Medicals Capital Expenditure for the year ending December 31, 2021 was USD -1.01 M, a -117.40% change year over year.
-
Great Novel Therapeutics Biotech & Medicals Capital Expenditure for the year ending December 31, 2020 was USD -464.66 K, a 0.00% change year over year.
-
Great Novel Therapeutics Biotech & Medicals Capital Expenditure for the year ending December 31, 2019 was USD 0.00.
Key data
| Date | Capital Expenditure | Free Cash Flow | Depreciation And Amortization | Deferred Income Tax |
|---|
Market news
Loading...
Taipei Exchange: 7427.TWO
| CEO | Dr. Chia-Nan Chen |
| IPO Date | July 8, 2021 |
| Location | |
| Headquarters | No.508, Zhongxiao East Road |
| Employees | 19 |
| Sector | Health Care |
| Industries | |
Description
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei City, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email